Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

Trump administration funding cuts and dismantling of USAID force the focus to shift from elimination back to treatment.

A new twice-yearly antiviral injection that can prevent HIV is likely to be approved soon in Australia. Making it affordable ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...

The approval of Yeztugo is a momentous step in improving PrEP options available for people vulnerable to contracting ...

The World Health Organization has added the variant, known formally as XFG, to its monitoring list. A dry, irritated throat ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

USAID has been present in Uganda for over sixty years. It has funded development in agriculture, education and research in ...